Get the Stockscreener App
23.29
2.92%
-0.70
Pre-market:
23.01
-0.28
-1.20%
Celldex Therapeutics Inc Stock (CLDX) Latest News
It is Poised to be a Bull Market for Celldex Therapeutics Inc (CLDX) - SETE News
Post-Trade Analysis: Celldex Therapeutics Inc (CLDX) Slides -2.11, Closing at 23.15 - The Dwinnex
Chronic Spontaneous Urticaria Market Set to Grow Substantially - openPR
Celldex Therapeutics Inc (CLDX)’s stock performance: a year in review - US Post News
Investing in Celldex Therapeutics Inc (CLDX): What You Must Know - Knox Daily
Checking in on Checkpoint Therapeutics Inc (CKPT) after recent insiders movement - Knox Daily
Stephens initates Catalyst Pharmaceuticals Inc (CPRX) stock to an Overweight - Knox Daily
Celldex Therapeutics (NASDAQ:CLDX) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by SG Americas Securities LLC - Defense World
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock outlook - Investing.com India
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential - MSN
Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential By Investing.com - Investing.com South Africa
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews - Benzinga
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Cantor Fitzgerald Forecasts CLDX FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts CLDX FY2025 Earnings - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Expands By 10.7% - MarketBeat
Analysts Provide Insight Into Celldex Therapeutics Inc’s (CLDX) Potential. - Stocks Register
B-cell Non-hodgkin Lymphoma Clinical and Non-Clinical - openPR
Celldex stock hits 52-week low at $22.89 amid market challenges By Investing.com - Investing.com South Africa
Celldex stock hits 52-week low at $22.89 amid market challenges - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month LowHere's What Happened - MarketBeat
Stifel maintains positive outlook on Celldex and Third Harmonic stocks By Investing.com - Investing.com Canada
Jasper’s Briquilimab Stands Up To Competition, But Investors Bail - News & Insights
Guggenheim maintains $90 target on Celldex stock after study By Investing.com - Investing.com Canada
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap UpHere's Why - MarketBeat
Before You Invest, Make Sure You Check This Asset Entities Inc (NASDAQ: ASST) Analysis - Stocks Register
What Do Wall Street Analysts Think About Celldex Therapeutics Inc (NASDAQ: CLDX) Stock? - Stocks Register
Why Is Jasper Therapeutics Stock Trading Lower On Wednesday?Jasper Therapeutics (NASDAQ:JSPR) - Benzinga
Celldex Therapeutics' SWOT analysis: barzolvolimab potential drives stock outlook By Investing.com - Investing.com Canada
Celldex Therapeutics’ SWOT analysis: barzolvolimab potential drives stock outlook By Investing.com - Investing.com Nigeria
Celldex Therapeutics' SWOT analysis: barzolvolimab potential drives stock outlook - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Given “Overweight” Rating at Cantor Fitzgerald - Defense World
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock potential in urticaria By Investing.com - Investing.com Nigeria
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria By Investing.com - Investing.com South Africa
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Drops By 5.1% - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Barclays PLC Has $4.43 Million Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
What Analysts Are Saying About Celldex Therapeutics Stock - Benzinga
Celldex Therapeutics' (CLDX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis - The Manila Times
Celldex Launches Pivotal Phase 2 Trial for Novel Atopic Dermatitis Treatment, Targeting 20% of US Population - StockTitan
State Street Corp Sells 173,932 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):